| Chronic Obstructive Airway Disease
Ohtuvayre vs Stiolto Respimat
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Ohtuvayre vs Stiolto Respimat with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStiolto Respimat has a higher rate of injection site reactions vs Ohtuvayre based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stiolto Respimat but not Ohtuvayre, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ohtuvayre
Stiolto Respimat
At A Glance
Oral inhalation
Twice daily
PDE3/PDE4 inhibitor
Oral inhalation
Once daily
LAMA/LABA
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
Dosing
Chronic Obstructive Airway Disease 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, via oral inhalation using a standard jet nebulizer with a mouthpiece.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema Two inhalations once-daily at the same time of day via the STIOLTO RESPIMAT inhaler; do not use more than two inhalations every 24 hours.
Contraindications
- Hypersensitivity to ensifentrine or any component of this product
- Use of LABA without inhaled corticosteroid in patients with asthma
- Hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product
Adverse Reactions
Most common (>=1%) Back pain, hypertension, urinary tract infection, diarrhea
Serious Paradoxical bronchospasm, psychiatric events including suicidality
Most common (>3%) nasopharyngitis, cough, back pain
Serious COPD exacerbation, pneumonia
Pharmacology
Ensifentrine is a dual inhibitor of PDE3 and PDE4 enzymes; inhibition results in accumulation of intracellular cAMP and/or cGMP, producing downstream bronchodilatory and anti-inflammatory signaling effects.
Stiolto Respimat combines tiotropium, a long-acting muscarinic antagonist that inhibits M3-receptors at airway smooth muscle to produce bronchodilation, and olodaterol, a LABA that activates beta2-adrenoceptors to stimulate cAMP synthesis and relax airway smooth muscle cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ohtuvayre
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Stiolto Respimat
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Ohtuvayre
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Stiolto Respimat
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Ohtuvayre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Stiolto Respimat
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Stiolto Respimat.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OhtuvayreView full Ohtuvayre profile
Stiolto RespimatView full Stiolto Respimat profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.